View in EDS HTML Full Text PDF Full Text

The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.

Saved in:
Bibliographic Details
Title: The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
Authors: Beyerlin K; Massachusetts General Hospital, Boston, MA, USA., Jimenez R; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Zangardi M; Massachusetts General Hospital, Boston, MA, USA., Fell GG; Dana-Farber Cancer Institute, Boston, MA, USA., Edmonds C; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Johnson A; Massachusetts General Hospital, Boston, MA, USA., Bossuyt V; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Specht M; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Mulvey TM; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Moy B; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Ellisen LW; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Isakoff SJ; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Bardia A; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Spring LM; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Source: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Dec; Vol. 27 (8), pp. 1883-1890. Date of Electronic Publication: 2020 Nov 05.
Publication Type: Journal Article
Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33153384
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Beyerlin+K%22">Beyerlin K</searchLink>; Massachusetts General Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Jimenez+R%22">Jimenez R</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Zangardi+M%22">Zangardi M</searchLink>; Massachusetts General Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Fell+GG%22">Fell GG</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Edmonds+C%22">Edmonds C</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Johnson+A%22">Johnson A</searchLink>; Massachusetts General Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bossuyt+V%22">Bossuyt V</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Specht+M%22">Specht M</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mulvey+TM%22">Mulvey TM</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Moy+B%22">Moy B</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ellisen+LW%22">Ellisen LW</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Isakoff+SJ%22">Isakoff SJ</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bardia+A%22">Bardia A</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Spring+LM%22">Spring LM</searchLink>; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229511372%22">Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</searchLink> [J Oncol Pharm Pract] 2021 Dec; Vol. 27 (8), pp. 1883-1890. <i>Date of Electronic Publication: </i>2020 Nov 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SAGE+Publications%22">SAGE Publications </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9511372 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1477-092X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210781552%22">10781552 </searchLink><i>NLM ISO Abbreviation: </i>J Oncol Pharm Pract <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33153384
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/1078155220971751
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1883
    Titles:
      – TitleFull: The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Beyerlin K
      – PersonEntity:
          Name:
            NameFull: Jimenez R
      – PersonEntity:
          Name:
            NameFull: Zangardi M
      – PersonEntity:
          Name:
            NameFull: Fell GG
      – PersonEntity:
          Name:
            NameFull: Edmonds C
      – PersonEntity:
          Name:
            NameFull: Johnson A
      – PersonEntity:
          Name:
            NameFull: Bossuyt V
      – PersonEntity:
          Name:
            NameFull: Specht M
      – PersonEntity:
          Name:
            NameFull: Mulvey TM
      – PersonEntity:
          Name:
            NameFull: Moy B
      – PersonEntity:
          Name:
            NameFull: Ellisen LW
      – PersonEntity:
          Name:
            NameFull: Isakoff SJ
      – PersonEntity:
          Name:
            NameFull: Bardia A
      – PersonEntity:
          Name:
            NameFull: Spring LM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1477-092X
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
              Type: main
ResultId 1